Farid Khalilov

Farid Khalilov

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2025 in Materials
Verified
Journal Article
Open access
PDF file
XHXulong Huang
Xulong Huang
WZWengang ZHao
Wengang ZHao
FKFarid Khalilov
Farid Khalilov
XNXu Nuo
Xu Nuo
Oxide (GO) has emerged as a highly versatile nanomaterial due to its exceptional physicochemical properties, including large surface area, and strong drug-loading capacity. These characteristics have enabled its broad application in fields such as wound healing, targeted drug delivery, and antimicrobial therapies. However, despite its promise, concerns surrounding GO’s cytotoxicity, biocompatibility, and potential pathological effects have limited its clinical translation. Addressing these limitations requires a deeper understanding of GO’s interactions with biological systems and the development of strategies to mitigate its adverse effects. Recent advances in surface functionalization, covalent crosslinking, and the incorporation of GO into biocompatible matrices have shown great potential in enhancing its performance while minimizing toxicity. This review provides a comprehensive overview of the antibacterial mechanisms of GO and highlights recent progress in chemical modification approaches that improve its efficacy in biomedical applications, particularly in wound healing and drug delivery. By critically examining both the advantages and limitations of GO, this work aims to inform future research directions and support the safe and effective integration of GO-based materials in advanced therapeutic systems.


13 July 2025 in Toxics
Verified
Journal Article
Open access
PDF file
JXJiali Xiao
Jiali Xiao
JWJunchao Wang
Junchao Wang
XNXu Nuo
Xu Nuo
XHXulong Huang
Xulong Huang
FKFarid Khalilov
Farid Khalilov
EKElchin Khalilov
Elchin Khalilov
Perfluorononanoic acid (PFNA) is a ubiquitous persistent environmental pollutant, and several studies have found significant links between atopic dermatitis (AD) and prenatal exposure to PFNA. However, the relationship between PFNA and AD remains unclear. In this study, 2,4-dinitrochlorobenzene (DNCB)-treated female BALB/c mice were used as AD models to investigate the effects of PFNA and its potential mechanisms. These mice were topically applied with 5 mg/kg PFNA per day for 15 days. The results demonstrated that PFNA significantly increased AD lesion severity and clinical symptoms, including dermatitis score, ear thickness, and epidermal thickness. In addition, PFNA also increased the serum IgE level, splenic atrophy, and upregulated the expression of TNF-α, IL-6, and IL-1β, genes that are associated with skin inflammatory factors. In addition, Western blot results showed that PFNA treatment upregulated the expression of p-JNK protein. Additionally, cellular experiments indicated that RAW264.7 macrophages and mouse brain microvascular endothelial (bEnd.3) cells treated with PFNA at concentrations of 0.01–100 μM for 72 h showed no changes in cell viability. However, 100 μM PFNA upregulated the mRNA expression levels of the pro-inflammatory cytokines IL-1β and IL-6, as well as the protein expression of p-JNK, in RAW264.7 cells induced with 1 mg/mL LPS for 2 h. Similarly, PFNA increased TNF-α and IL-6 mRNA expression and p-JNK protein expression in bEnd.3 cells stimulated with 20 ng/mL TNF-α for 0.5 h. Based on these findings, we can conclude that PFNA may aggravate atopic dermatitis by promoting inflammation.